The Catalyst® Cortisol
Test provides veterinarians with real-time critical insights when
evaluating dogs for Addison's
disease and Cushing's
syndrome
WESTBROOK, Maine, June 5, 2025
/PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global
leader in pet healthcare innovation, today announced the launch of
the Catalyst® Cortisol Test, which measures
real-time quantitative cortisol concentrations to support the
diagnosis of Addison's disease and
diagnosis and management of Cushing's syndrome in dogs. IDEXX's Catalyst
Cortisol Test is the third menu expansion in under a year for the
Catalyst platform, further advancing the diagnostic capabilities
available to veterinary practices at the point-of-care.
Addison's disease, often called
"the great pretender," is a life-threatening condition caused by
low cortisol and is difficult to diagnose due to its common and
nonspecific clinical signs that can resemble those of other
illnesses, such as gastroenteritis or kidney disease. Early
detection is critical, as timely treatment can be lifesaving.
Cushing's syndrome, driven by
excess cortisol, is a common endocrine disorder in older dogs, and
certain breeds are at an increased risk. Cushing's syndrome requires long-term
management, and if left untreated, it can significantly diminish
quality of life.
IDEXX's Catalyst Cortisol Test enables veterinarians to
confidently and accurately diagnose or rule out Addison's disease and Cushing's syndrome during the patient visit,
allowing for immediate treatment or adjustments to ongoing care
management. This workflow efficiency continues throughout the
patient journey with monitoring capabilities that enable tailored
treatment adjustments, improving long-term care for patients with
Cushing's syndrome.
"The Catalyst Cortisol Test is an accurate and highly requested
test that addresses a critical need for our customers and equips
veterinarians with built-in results interpretation for prompt
action, supporting better health outcomes for dogs," said
Jay Mazelsky, President and Chief
Executive Officer of IDEXX. "Continuing to expand the Catalyst
platform reinforces our Technology for Life promise, offering our
customers solutions that advance in capabilities over time to
expand clinical insights and care delivery at the
point-of-care."
The IDEXX Catalyst Cortisol Test features:
- Accuracy: Provides quantitative results in-clinic that
align with IDEXX Reference Laboratories, enabling veterinarians to
confidently diagnose or rule out Addison's disease and Cushing's syndrome.
- Interpretive guidance: Integrates with the IDEXX
Vetlab® Station and VetConnect® PLUS,
providing results-specific interpretation in real-time during the
patient visit.
- Efficiency: The Catalyst Cortisol Test's load-and-go
workflow can run alone or with additional chemistry tests using a
single sample for comprehensive diagnostic insights into patient
health status. This workflow saves hands-on sample preparation time
for veterinary technicians and ensures repeatable results.
"A reliable in-house test is game-changing—it enables faster
diagnosis and treatment of a life-threatening Addisonian crisis in
dogs," said Patty Lathan, VMD, MS,
DACVIM (SAIM).* "Additionally, by delivering accurate results
during the visit, it supports timely care and streamlines daily
workflows for busy veterinary teams."
The Catalyst Cortisol Test will be available in the U.S. and
Canada at the end of July 2025, with a global rollout to the installed
base of more than 75,000 Catalyst chemistry analyzers expected to
start in the third quarter of 2025. For more information, visit the
IDEXX Catalyst test menu web page.
About IDEXX
IDEXX Laboratories, Inc., is a global
leader in pet healthcare innovation. Our diagnostic and software
products and services create clarity in the complex, constantly
evolving world of veterinary medicine. We support longer, fuller
lives for pets by delivering insights and solutions that help the
veterinary community around the world make confident decisions—to
advance medical care, improve efficiency, and build thriving
practices. Our innovations also help ensure the safety of milk and
water across the world and maintain the health and well-being of
people and livestock. IDEXX Laboratories, Inc. is a member of the
S&P 500® Index. Headquartered in Maine, IDEXX employs approximately 11,000
people and offers solutions and products to customers in more than
175 countries and territories. For more information about IDEXX,
visit: www.idexx.com.
Note Regarding Forward-Looking Statements
This news
release contains or may contain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements can be identified by the use of
words such as "expects," "may," "anticipates," "intends," "would,"
"will," "plans," "believes," "estimates," "should," "project," and
similar words and expressions. These forward-looking statements are
intended to provide our current expectations or forecasts of future
events; are based on current estimates, projections, beliefs, and
assumptions; and are not guarantees of future performance. Actual
events or results may differ materially from those described in the
forward-looking statements. These statements are subject to risks,
uncertainties, assumptions, and other important factors. Readers
are cautioned not to put undue reliance on such forward-looking
statements because actual results may vary materially from those
expressed or implied. The reports filed by IDEXX pursuant to
United States securities laws
contain discussions of some of these risks and uncertainties. IDEXX
assumes no obligation to, and expressly disclaims any obligation
to, update or revise any forward-looking statements, whether as a
result of new information, future events, or otherwise. Readers are
advised to review IDEXX's filings with the United States Securities
and Exchange Commission (which are available from the SEC's EDGAR
database at sec.gov and via IDEXX's website at idexx.com).
*Dr. Lathan has received compensation for consulting services
she has provided to IDEXX from time to time.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/third-expansion-of-idexxs-catalyst-platform-in-under-a-year-delivers-critical-insights-to-veterinarians-evaluating-canine-patients-for-endocrine-disorders-302472370.html
SOURCE IDEXX Laboratories, Inc.